Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

cancer drugs pricing

- PMLiVE

Novartis announces $300m investment to boost development of next-generation biotherapeutics

The multi-year investment will be implemented across the company’s existing locations in Switzerland, Slovenia and Austria

- PMLiVE

Novartis and BeiGene announce positive phase 3 trial results for hepatocellular carcinoma treatment

Hepatocellular carcinoma accounts for 75-85% of liver cancer diagnoses

- PMLiVE

Novartis and Kaiku Health expand digital health monitoring partnership

The expansion aims to provide improved cancer care to a wider group of patients spanning multiple indications

- PMLiVE

Novartis’ Scemblix receives EC approval for chronic myeloid leukaemia

It is estimated that more than 6,300 people will be diagnosed with CML in Europe every year

- PMLiVE

Novartis to temporarily suspend Huntington’s disease phase 2b study after side effects reported

A data review found that branaplam may cause peripheral neuropathy, which is the result of nerve injury outside the brain and spinal cord

- PMLiVE

Novartis to separate generic drugs division Sandoz to create standalone company

The spin-off will allow shareholders to participate fully in the potential future upside of both companies

- PMLiVE

Medscape Education Invites Clinicians to Connect to the Conversation With New Mental Health and Wellness Learning Center

Medscape Education, the leading destination for continuous professional development for healthcare professionals, has launched Building Bridges Between Mental Health and Wellness, a learning center focusing on mental health and wellness for both patients...

Medscape Education Global

- PMLiVE

Novartis reports death of two patients treated with Zolgensma

The company has notified health authorities in markets where the drug is sold and has informed relevant healthcare professionals

- PMLiVE

Novartis’ Pluvicto receives MHRA marketing authorisation to treat advanced prostate cancer

The approval for the treatment applies to England, Scotland and Wales

- PMLiVE

NICE recommends Novartis’ Piqray in combination with Faslodex for advanced breast cancer patients

Around 2,800 breast cancer patients in England and Wales could benefit from the treatment

- PMLiVE

Novartis announces positive phase 3 trial results for advanced oesophageal cancer

Results from the study showed tislelizumab plus chemotherapy significantly improved overall survival for patients, regardless of PD-L1 status

- PMLiVE

Connect to the conversation around mental health: A spotlight on physician burnout

For more than 2 years, the COVID-19 pandemic has put emphasis on an issue that has long affected healthcare workers and physicians -- burnout. Every year, Medscape surveys thousands of...

Medscape Education Global

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links